Results 21 to 30 of about 367 (113)
Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment [PDF]
Frontiers in Pharmacology, 2023 One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their characteristic adverse reactions, in particular thrombocytopenia.
Bi Li +5 more
doaj +2 more sources
Pharmaceuticals, 2022 To develop and verify a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determining contezolid in plasma and cerebrospinal fluid (CSF). Protein precipitation was performed on samples using linezolid as the internal standard.
Guanxuanzi Zhang +4 more
doaj +2 more sources
Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats [PDF]
Drugs in R&DBackground & Objectives Contezolid (MRX-I) is a novel ortho-fluorophenyl dihydropyridone developed by MicuRx Pharmaceuticals, Inc. It has been approved for the treatment of drug-resistant Gram-positive bacterial infections with relatively lower toxicity ...
Liping Wei +8 more
doaj +2 more sources
Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus [PDF]
Frontiers in Cellular and Infection Microbiology, 2023 ObjectiveTo evaluate contezolid (MRX-I) antibacterial activity against Mycobacterium abscessus in vitro and in vivo and to assess whether MRX-I treatment can prolong survival of infected zebrafish.MethodsMRX-I inhibitory activity against M.
Shan. Gao +9 more
doaj +2 more sources
Safety and Tolerability of Contezolid Versus Linezolid for Short-Term Treatment of Rifampicin-Resistant Pulmonary Tuberculosis: A Randomized Controlled Study [PDF]
Infection and Drug ResistanceJun Wang,* Yu Xue,* Wenjuan Nie, Liping Ma, Naihui Chu, Yadong Du Tuberculosis Department, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of China&
Wang J, Xue Y, Nie W, Ma L, Chu N, Du Y
doaj +2 more sources
Health Technology Assessment of Oxazolidinones for MRSA-Associated Complicated Skin and Soft Tissue Infections [PDF]
Drug Design, Development and TherapyYucheng Zhao, Baisen Huang, Zunchang Yang, Hongjie Kuang, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key ...
Zhao Y, Huang B, Yang Z, Kuang H, Chen J
doaj +2 more sources
Infection and Drug Resistance, 2023 Sheng Zhao, Wei Zhang, Linfei Zhang, Jing Zhang, Jinghang Li, Linjie Si, Yi Ding, Mingke Li, Yuanyuan Song Department of Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, People’s ...
Jinghang Li
exaly +2 more sources
Frontiers in Medicine, 2023 BackgroundContezolid is a novel oxazolidinone antibacterial agent, but there have been no reports of any pertinent clinical studies for the treatment of tuberculosis (TB).
Liping Ma
exaly +3 more sources
The Therapeutic Effect of Contezolid in Complex Intra-Abdominal Infections [PDF]
Infection and Drug ResistanceYongsheng Zhao,* Xianlei Xin,* Bin Wang, Lei He, Qinghua Zhao, Weizheng Ren Faculty of Hepato-Pancreato-Biliary Surgery, First Medical Center, Chinese PLA General Hospital, Beijing, People’s Republic of China*These authors contributed equally
Zhao Y +5 more
doaj +1 more source
Infection and Drug Resistance, 2022 Yixin Kang,1,* Cheng Ge,2,* Huan Zhang,3 Saizhe Liu,4 Hongyang Guo,4 Junchang Cui1 1Department of Respiratory Diseases, the First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of China ...
Yixin Kang, Junchang Cui
exaly +2 more sources